A reversed-phase high performance liquid chromatographic (RP-HPLC) method wasdeveloped and validated for the simultaneous deteimination of ceftazidime and tazobactam ininject-able powder. Methods Chromatography was ca...A reversed-phase high performance liquid chromatographic (RP-HPLC) method wasdeveloped and validated for the simultaneous deteimination of ceftazidime and tazobactam ininject-able powder. Methods Chromatography was carried out on Zorbax 300SB-C_(18) column using amixture of methanol and aqueous solution of phosphate buffer (pH = 5.6) as mobile phase. The UVdetection wavelength was 220 run. Results The linear ranges of ceftazidime and tazobactam were 0.62- 631.8 μg·mL^(-1) and 0.66 - 677.50 μg·mL^(-1), respectively. The average recoveries were 98.8%- 101.4% for ceftazidime, and 99,1% - 100.2% for tazobactam. The RSD values of inter-day andintra-day assays were lower than 1.5% for ceftazidime and 2.6% for tazobactam. Conclusion Thismethod is reproducible, simple, precise, and rapid for the quality control of ceftazidime andtazobactam in injectable powder.展开更多
Melioidosis,a disease of public health importance in Southeast Asia and Northern Australia,of late has shown an increasing trend in India,particularly Southern India.We describe a ease of a 39-year-old diabetic patien...Melioidosis,a disease of public health importance in Southeast Asia and Northern Australia,of late has shown an increasing trend in India,particularly Southern India.We describe a ease of a 39-year-old diabetic patient with left elbow septic arthritis,multiple liver,splenic abscesses, pneumonia,pleural effusion,followed by sepsis syndrome.Blood cultures and culture of the joint aspirate yielded pure growth of Burkholderia psettdomallei(B.pesudomallei),sensitive to carbapenem,co-trimoxazole and resistant to ceftazidime.The patient was successfully treated with imipenem- cilastin.He was discharged on co-trimoxazole to complete the 24 weeks course and follow-up has continued to date.The patient continues to remain asymptomatic.The case re-emphasizes the need to monitor the trend of B.pseudomallei in India,particularly the development of ceftazidime resistance,which incidentally is the drug of choice.展开更多
We present a case of keratitis caused by Stenotrophomonas maltophilia in a therapeutic contact lens user with trichiasis and symblepharon. This keratitis was initially diagnosed as caused by Achromobacter xylosoxidans...We present a case of keratitis caused by Stenotrophomonas maltophilia in a therapeutic contact lens user with trichiasis and symblepharon. This keratitis was initially diagnosed as caused by Achromobacter xylosoxidans, but the strain was sent for species confirmation and the isolate was finally identified as S. maltophilia by means of 16S rDNA sequencing. The patient rapidly improved on administration of fortified ceftazidime. Physicians should be aware that the definitive identification of the pathogenic agent and prolonged antimicrobial treatment according to culture sensitivities in keratitis are mandatory as treatment success depends greatly on them.展开更多
The antimicrobial susceptibility testing was performed with Kirby-Bauer disc diffusion and agar diffusion methods, and the crude β-lactamase was extracted by sonication with its isoelectric point （pI） determined wi...The antimicrobial susceptibility testing was performed with Kirby-Bauer disc diffusion and agar diffusion methods, and the crude β-lactamase was extracted by sonication with its isoelectric point （pI） determined with isoelectric focusing, and purified by two steps of chromatography. The genome DNA fragments of bacterial strains were amplified with PCR and subjected to sequencing. The kinetic parameters for β-lactamase were detected by spectrophoto metric method. It was found that the bacterial strains isolated from clinical specimens were resistant to penicillin, ceftazidine, cefotaxime and azitreonam, but sensitive to imipenem and cefoxitin, in which two resistant strains to ceftazidine were found to produce a single extended spectrum β-lactamase（ESBL） with pI value of 8.7. Results of cloning and sequencing of the β-lactamase encoding gene showed that this gene was similar to blactx-m-l with 6 point mutations including 3 silent mutations. The amino acid sequence derived from the nucleic acid data indicated that this enzyme was distinct from β-lactamse CTX-M-1 by 3 amino acids, i.e. Val-80→Ala, Asp-117→Asn and Ser-143→Ala（CTX-M-Ⅳ）. Molecular weight of this enzyjne was 29 kDa. Kinetic analysis of the partially purified β-lactamase confirmed that this enzyine was ＇able to hydrolyze cefotaxime and aztreonanl, but not to imipenem. In addition, the the β-lactamase was well inhibited by sulbactam（IC50 94 nM） and tazobactam（IC50 5 nM）. It is concluded that CTX-M-Ⅳ is a CTX-M-type extended spectrum β-lactamase.展开更多
文摘A reversed-phase high performance liquid chromatographic (RP-HPLC) method wasdeveloped and validated for the simultaneous deteimination of ceftazidime and tazobactam ininject-able powder. Methods Chromatography was carried out on Zorbax 300SB-C_(18) column using amixture of methanol and aqueous solution of phosphate buffer (pH = 5.6) as mobile phase. The UVdetection wavelength was 220 run. Results The linear ranges of ceftazidime and tazobactam were 0.62- 631.8 μg·mL^(-1) and 0.66 - 677.50 μg·mL^(-1), respectively. The average recoveries were 98.8%- 101.4% for ceftazidime, and 99,1% - 100.2% for tazobactam. The RSD values of inter-day andintra-day assays were lower than 1.5% for ceftazidime and 2.6% for tazobactam. Conclusion Thismethod is reproducible, simple, precise, and rapid for the quality control of ceftazidime andtazobactam in injectable powder.
文摘Melioidosis,a disease of public health importance in Southeast Asia and Northern Australia,of late has shown an increasing trend in India,particularly Southern India.We describe a ease of a 39-year-old diabetic patient with left elbow septic arthritis,multiple liver,splenic abscesses, pneumonia,pleural effusion,followed by sepsis syndrome.Blood cultures and culture of the joint aspirate yielded pure growth of Burkholderia psettdomallei(B.pesudomallei),sensitive to carbapenem,co-trimoxazole and resistant to ceftazidime.The patient was successfully treated with imipenem- cilastin.He was discharged on co-trimoxazole to complete the 24 weeks course and follow-up has continued to date.The patient continues to remain asymptomatic.The case re-emphasizes the need to monitor the trend of B.pseudomallei in India,particularly the development of ceftazidime resistance,which incidentally is the drug of choice.
文摘We present a case of keratitis caused by Stenotrophomonas maltophilia in a therapeutic contact lens user with trichiasis and symblepharon. This keratitis was initially diagnosed as caused by Achromobacter xylosoxidans, but the strain was sent for species confirmation and the isolate was finally identified as S. maltophilia by means of 16S rDNA sequencing. The patient rapidly improved on administration of fortified ceftazidime. Physicians should be aware that the definitive identification of the pathogenic agent and prolonged antimicrobial treatment according to culture sensitivities in keratitis are mandatory as treatment success depends greatly on them.
文摘The antimicrobial susceptibility testing was performed with Kirby-Bauer disc diffusion and agar diffusion methods, and the crude β-lactamase was extracted by sonication with its isoelectric point （pI） determined with isoelectric focusing, and purified by two steps of chromatography. The genome DNA fragments of bacterial strains were amplified with PCR and subjected to sequencing. The kinetic parameters for β-lactamase were detected by spectrophoto metric method. It was found that the bacterial strains isolated from clinical specimens were resistant to penicillin, ceftazidine, cefotaxime and azitreonam, but sensitive to imipenem and cefoxitin, in which two resistant strains to ceftazidine were found to produce a single extended spectrum β-lactamase（ESBL） with pI value of 8.7. Results of cloning and sequencing of the β-lactamase encoding gene showed that this gene was similar to blactx-m-l with 6 point mutations including 3 silent mutations. The amino acid sequence derived from the nucleic acid data indicated that this enzyme was distinct from β-lactamse CTX-M-1 by 3 amino acids, i.e. Val-80→Ala, Asp-117→Asn and Ser-143→Ala（CTX-M-Ⅳ）. Molecular weight of this enzyjne was 29 kDa. Kinetic analysis of the partially purified β-lactamase confirmed that this enzyine was ＇able to hydrolyze cefotaxime and aztreonanl, but not to imipenem. In addition, the the β-lactamase was well inhibited by sulbactam（IC50 94 nM） and tazobactam（IC50 5 nM）. It is concluded that CTX-M-Ⅳ is a CTX-M-type extended spectrum β-lactamase.
